Table 4.
Comparing Capreomycin, Amikacin, and Kanamycin (Susceptible Only)
| Drug | Events/Total | Events/Total | Pairs, No. | Odds Ratio (95% CI) |
Risk Difference (95% CI)a |
|---|---|---|---|---|---|
| Amikacin vs kanamycin | Amikacin | Kanamycin | |||
| Cured | 1302/1394 | 2192/2523 | 1394 | 2.0 (1.5–2.5) | 0.06 (.04–.08) |
| Died | 250/1644 | 435/2958 | 1643 | 0.7 (.6–.8) | −0.02 (−.04 to .01) |
| Comparison in fluoroquinolone-resistant subgroup | |||||
| Cured | 168/186 | 178/213 | 172 | 2.0 (1.0–3.8) | 0.08 (.01–.15) |
| Died | 43/229 | 39/252 | 216 | 0.8 (.5–1.3) | 0.02 (−.05 to .10) |
| Capreomycin vs amikacin | Capreomycin | Amikacin | |||
| Cured | 821/938 | 1302/1394 | 938 | 0.3 (.2–.4) | −0.09 (−.11 to −.06) |
| Died | 176/1114 | 250/1644 | 1113 | 1.7 (1.3–2.2) | 0.05 (.02–.08) |
| Comparison in fluoroquinolone-resistant subgroup | |||||
| Cured | 118/168 | 168/186 | 160 | 0.3 (.2–.5) | −0.20 (−.30 to −.11) |
| Died | 52/220 | 43/229 | 216 | 1.8 (1.1–2.9) | 0.04 (−.04 to .12) |
| Capreomycin vs kanamycin | Capreomycin | Kanamycin | |||
| Cured | 821/938 | 2192/2523 | 938 | 0.8 (.6–1.0) | −0.02 (−.05 to .01) |
| Died | 176/1114 | 435/2958 | 1114 | 0.8 (.6–1.0) | 0.01 (−.02 to .04) |
| Comparison in fluoroquinolone-resistant subgroup | |||||
| Cured | 118/168 | 178/213 | 168 | 0.8 (.5–1.2) | −0.05 (−.15 to .05) |
| Died | 52/220 | 39/252 | 220 | 1.0 (.7–1.6) | 0.12 (.05–.20) |
Excluded: 857 who received ≥ 2 injectables for no clear reason. Included: 613 no injectables, 10 307 who received only 1 injectable, and 253 who were switched to an effective second-line injectable drug based on drug susceptibility test results.
Values in bold are statistically significant (P < .05), meaning that 95% CI do not include 1.0 for odds ratios, or do not include 0 for risk differences.
Abbreviation: CI, confidence interval.
aEffect adjusted for age, sex, human immunodeficiency virus status, acid-fast smear microscopy results, cavities on chest radiograph, prior treatment with first- and second-line tuberculosis drugs, and resistance to fluoroquinolones or second-line injectables, and number of possibly effective drugs in the initial phase. In all models, odds ratios were estimated with random-effects model (intercept and slope), but risk differences were estimated with fixed-effects models as random-effects models would not converge.